Hero image with Pittsburgh background pittplusme.org/study/2165

STUDY BASICS

Are you 18-75 years old? Do you have psoriasis? You may be able to participate in a study find out whether switching between ABP 501 (Amjevita®) and adalimumab (Humira®) treatments results in a similar effect on your psoriasis when compared with the use of adalimumab alone. Participation in this study will last up to 9 months. Compensation is provided.


IRB: SSU00165462
- Amgen - 20200497 / 260859, A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared with Continued Use of Adalimumab in Subjects with Moderate to Severe Plaque (Pro00055441)

PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit pittplusme.org/study/2165 and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.